EICHORPublic-registry site landscape for NCT06208150, “A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide”, a Multiple Myeloma study sponsored by Janssen Research & Development, LLC. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT06208150 (registry record) |
| Study title | A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide |
| Official title | 64407564MMY3009: A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pom |
| Sponsor | Janssen Research & Development, LLC |
| Condition(s) | Multiple Myeloma |
| Phase | PHASE3 |
| Listed sites | 242 |
| Site countries | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, France, Germany |
Patient-friendly overview of this study: eichor.com/study/NCT06208150.
Eichor generates a preliminary site-risk snapshot for NCT06208150 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Multiple Myeloma trials
More from Janssen Research & Development, LLC
← Eichor home · All tracked trials · Multiple Myeloma studies · Weekly briefs
